Guggenheim analyst Eddie Hickman raised the firm’s price target on Tarsus Pharmaceuticals (TARS) to $84 from $78 and keeps a Buy rating on the shares. The firm has updated its model to reflect the updated spend, script volume, and GTN guidance following the company’s Q1 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TARS:
- Tarsus Pharmaceuticals Reports Strong Q1 2025 Growth
- Tarsus Pharmaceuticals reports Q1 EPS (64c), consensus (63c)
- Tarsus Pharmaceuticals to present abstracts on XDEMVY at ASCRS meeting
- Tarsus Pharmaceuticals 2.809M share Spot Secondary priced at $44.50
- Tarsus Pharmaceuticals announces $100M common stock offering